Biologics, Targeted Therapies Best for Acute PsA Dactylitis
Following treatment, ‘fat fingers/toes’ returned after a median of 2 years in one third of patients.
Related Articles
Day in the Life: Clinical Trialist Drives Next-Gen AML Care
Naval Daver, MD, a hematologist-oncologist who has led more than 100 clinical trials, predicts the next 5 years will see successful development of cellular therapies…
Skills Lab: Understanding Misconceptions About PFS in Cancer Care
Dr Bishal Gyawali discusses how physicians and patients understand surrogate endpoints, and whether appropriate clinical decisions are made on the basis of this understanding.
Should Adults Update Their Measles Vaccinations?
Despite recent outbreaks, most adults who were vaccinated as children or previously in adulthood remain at low risk.
HIV-1 Vaccine Shows Strong T-Cell Response in Phase 1 Study
According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African participants who bear the highest burden of HIV-1.
2 New Studies Show CVD Benefit of Portfolio Diet
The plant-based, cholesterol-lowering diet is associated with a reduced risk for cardiovascular disease and mortality across diverse groups.
Epilepsy May Signal Future Dementia Risk
Epilepsy prevalence is significantly higher among people with frontotemporal dementia, with some patients reporting epilepsy up to 10 years before diagnosis of frontotemporal dementia.
Norovirus GII.17 Takes the Lead in Recent US Outbreaks
The GII.17 genotype may drive earlier start to norovirus season
FDA Bucks Advisors to Approve Mitomycin for Non-Muscle Invasive Bladder Cancer
The agency set aside concerns about UroGen’s approval trial to greenlight mitomycin intravesical solution for recurrent non-muscle invasive bladder cancer.
The Undervalued Medical Power of Muscle
We focus on looks and performance, but muscle’s metabolic, anti-inflammatory, and disease-resisting properties make it an available, improvable key to better health.